PT - JOURNAL ARTICLE AU - Chen, Hao-Huan AU - Chen, Wei-Fan AU - Hsieh, Yhu-Chia AU - Chen, Chih-Jung TI - Prevalence of neutralizing antibody to human coronavirus 229E in Taiwan AID - 10.1101/2022.03.21.22272725 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.21.22272725 4099 - http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272725.short 4100 - http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272725.full AB - Background Four members in the Coronaviruses family including 229E circulating in the community were known to cause mild respiratory tract infections in humans. The epidemiologic information of the seasonal human coronavirus (HCoV) may help gain insight into the development of the ongoing pandemic of coronavirus disease since 2019 (COVID-19).Methods Plasma collection containing 1558 samples was obtained in 2010 for an estimate of the prevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan. Of 1558 samples, 200 were randomly selected from those aged < 1 year to > 60 years. The neutralizing antibody titers to HCoV-229E were determined in the serums using live virus ATCC® VR-740™ cultivating in the Huh-7 cell line.Results Seroconversion of HCoV-229E (titer ≥ 1:2) was identified as early as less than 5 years of age. Among 140 subjects aged younger than or equal to 40 years, all of them had uniformly low titers (< 1:10) and the geometric mean titers (GMTs) were not significantly different for those aged 0-5, 6-12, 13-18 and 19-40 years (P > 0.1). For 60 subjects greater than 40 years old, a majority (39, 65%) of them had high titers ≥ 1:10 and the GMTs were significantly increased with advanced age (P < 0.0001). Age was the most significant factor predicting seropositivity in the multivariate analysis, with an adjusted odds ratio of 1.107 and a 95% adjusted confidence interval of 1.061–1.155 (P < 0.0001).Conclusion HCoV-229E infection occurred as early as younger than 5 years old in Taiwanese and the magnitudes of neutralizing titers against HCoV-229E increased with advanced age beyond 40 years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was partly supported by grants from Ministry of Science and Technology in Taiwan (MOST 108-2314-B-182A-055, MOST109-2320-B-182A-015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institute review boards in Chang Gung Memorial Hospital (202100266B0). A wavier of inform consent was granted given the retrospective nature of the project and anonymous analysis of the samples and the demographic information.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript